NDAORALTABLET
Approved
Jun 2003
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
5/8 — Partial
STALEVO 75 (carbidopa, levodopa, and entacapone) by Orion Pharma is catechol o-methyltransferase inhibitors [moa]. Approved for catechol-o-methyltransferase inhibitor [epc]. First approved in 2003.
Drug data last refreshed 10h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
STALEVO 75 is an oral tablet combining carbidopa, levodopa, and entacapone for Parkinson's disease management. Levodopa is converted to dopamine in the brain to restore motor function, while carbidopa prevents peripheral breakdown and entacapone extends levodopa availability by inhibiting catechol O-methyltransferase. This triple combination reduces motor fluctuations in patients experiencing wearing-off effects.
$0.018BPart D
LOE ApproachingDeclining
As LOE approaches, STALEVO 75 faces commercialization contraction; teams should anticipate resource reallocation and transition planning.
Mechanism of Action
Catechol O-Methyltransferase Inhibitors
Pharmacologic Class:
Catechol-O-Methyltransferase Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Levodopa Concentration Profile With Stalevo 75/125 mg
Started Dec 2009
20 enrolled
Parkinson's Disease
Career Relevance
Working on STALEVO 75 positions professionals in a mature, stable product requiring defensive commercial strategies and LOE preparation rather than growth initiatives. Career advancement depends on demonstrating expertise in competitive defense, generic mitigation, and organizational restructuring during transition phases.
Brand Manager
Worked on STALEVO 75 at Orion Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.